Evidence map›Paper›PMID 40620186›Full record

ArticleCancer reports (Hoboken, N.J.)2025

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.

Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yugo MatsumuraDepartment of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Seiya IchiharaDepartment of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Kaori NiiDepartment of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Kazumasa NanjoDepartment of Thoracic Surgery, National Hospital Organization Kochi Hospital, Kochi, Japan.
Naoki KadotaDepartment of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Yoshio OkanoDepartment of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Hisanori MachidaDepartment of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Nobuo HatakeyamaDepartment of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Hiroyuki HinoDepartment of Thoracic Surgery, National Hospital Organization Kochi Hospital, Kochi, Japan.
Keishi NaruseDepartment of Pathology, National Hospital Organization Kochi Hospital, Kochi, Japan.
Tsutomu ShinoharaDepartment of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima, Japan.
Shoji SakiyamaDepartment of Thoracic Surgery, National Hospital Organization Kochi Hospital, Kochi, Japan.
Eiji TacheuchiDepartment of Clinical Investigation, National Hospital Organization Kochi Hospital, Kochi, Japan.ORCID 0000-0003-1541-9747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for EGFR-mutated squamous cell lung carcinoma. We herein present a case of EGFR-mutated squamous cell lung carcinoma that responded to osimertinib. CASE: A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an EGFR mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.

conclusionWe encountered a rare EGFR-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with EGFR-mutated squamous cell lung carcinoma.

Indexed as

AcrylamidesAniline CompoundsCarcinoma, Squamous CellLung NeoplasmsAgedErbB ReceptorsFemaleHumansIndolesMutationProtein Kinase InhibitorsPyrimidinesTomography, X-Ray ComputedTreatment OutcomeAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesEGFR mutationEGFR‐TKIL858Rosimertinibsquamous cell lung cancer

Identifiers

PMID40620186
PMCPMC12230503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.